# GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC

> **NCT05019677** · PHASE2 · WITHDRAWN · sponsor: **Fudan University**

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** GP+PD-1+Tight

## Key facts

- **NCT ID:** NCT05019677
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Repeat registration
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05019677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05019677, "GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05019677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*